New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:37 EDTGALTGalectin Therapeutics volatility elevated into results from fatty liver disease
Galectin Therapeutics April call option implied volatility is at 234, May is at 143, July is at 115; compared to its 26-week average of 101 according to Track Data, suggesting large near term price movement into reporting results from the first cohort of its Phase 1 clinical trial examining GR-MD-02 in fatty liver disease.
News For GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for GALT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use